Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
about
Hysterectomy versus hysterectomy plus oophorectomy for premenopausal womenStructural determinants of the BRCA1 : estrogen receptor interactionFamily information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutationsCommon breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersBRCA mutations and childhood cancer25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational researchThe origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.Oestrogen exposure and breast cancer riskPatterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation.Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionThe Consequences of a BRCA Mutation in WomenBRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?BRCA1, a 'complex' protein involved in the maintenance of genomic stabilityPlant sterols as anticancer nutrients: evidence for their role in breast cancerCancer biomarkersRisk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriersThe oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.Characterization of BRCA1 and BRCA2 mutations in a large United States sampleVariation in breast cancer risk in BRCA1 and BRCA2 mutation carriersPre-counseling education for low literacy women at risk of Hereditary Breast and Ovarian Cancer (HBOC): patient experiences using the Cancer Risk Education Intervention Tool (CREdIT).Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.An overview of optical coherence tomography for ovarian tissue imaging and characterization.Correlating optical coherence elastography based strain measurements with collagen content of the human ovarian tissue.Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group studyOral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Potential role of coregistered photoacoustic and ultrasound imaging in ovarian cancer detection and characterization.The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study.Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.Progress and challenges in screening for early detection of ovarian cancer.Do breast cancer survivors benefit from prophylactic removal of uterus and ovaries? A population-based data linkage replication study.Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage.Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Incorporating medical interventions into carrier probability estimation for genetic counseling.BRCA1 interaction with human papillomavirus oncoproteins.Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
P2860
Q24194792-A4B4B0B7-704B-4FAB-A4DD-B90D820CBF3BQ24292926-D342550F-42CB-4884-B401-04039C5078ADQ24655010-383D3F96-C87F-437D-980F-B547C0C16DE7Q24655824-6BDF3A79-3DAC-4599-805F-F475F2E4D224Q24655952-4B7F93E9-6DDC-4C4B-99D8-5CD2F495A091Q24795635-56E4A719-7C9C-45E5-903B-165364929030Q24796156-51312927-A76F-4E37-9E16-15EECF50CE1FQ24803498-F4DBAF66-2D11-43FD-9779-D9C4C5FC76C2Q25257326-6F197969-D4D8-46C6-8E00-3C918DE1F6EFQ25257803-91C28115-17A3-47ED-A9EC-62A32F2065C0Q26744525-107DEF69-A98F-4961-BC77-59AA4B970306Q26747279-EF5F86E6-BEA1-4D16-980D-23BFC57BA525Q26777891-31DC12CE-CD54-4737-965B-77B8F4220955Q26822737-A63EC0A6-A772-4F95-A1DF-5B9486A8E2C4Q26853262-2FDDF21A-54ED-47C3-9217-AD3195A8BD13Q26861053-6734BFA8-189D-4FA2-BAC9-87820E3E3B59Q26864429-4395D57A-F60B-4299-B6F0-8123CDC0CC41Q27003935-0606D0E2-25DD-494E-B0D3-404693C91697Q27025315-579CA03C-345E-4BC1-8AF0-59B544F989E1Q27316521-95B7A1E7-362A-4275-B3CA-132FDB213C39Q28383993-F65BF0FB-E692-41FA-8577-AE011D41D936Q28386156-88A78F8D-1FE9-4BB9-92EB-514E32F4762FQ30227158-28286DD8-848A-4F8F-9B74-14F973CE7B3AQ30370475-13A64B05-0703-4A71-B4D0-B4A1CB2297C5Q30395093-54E094F7-81FC-41FA-A7FD-4B1A484FA89CQ30400512-D43D295F-27F3-4DC5-ACE3-5B1BAF75AA26Q30423597-BC3F29C0-EDD6-44DE-B1AA-D295736EA330Q30431721-EE374858-D580-4C57-832F-782C4C1ADA8AQ30433319-A1EF2269-7503-4B9B-A779-CD01A52A30DAQ30477398-0FD6BCDB-EEED-461A-96C7-1EBDD007A1EBQ30677729-EB76C58B-BD53-4BE7-ACB6-C49476484F30Q30764147-F65538D8-AF7D-4217-8235-CCA87E731838Q31041170-E738BA3F-6064-478A-AEE8-2BE85396F5FEQ31102791-DCCC40B4-19E2-4409-9378-09DB2B0081BBQ33221678-88B19114-D423-4B81-8F73-26B24DD54B66Q33237559-B6BEF87F-1BD7-4602-ADF9-D5439322A627Q33279688-38145D97-22B1-4B23-8C98-F0EB9B6232AEQ33292263-55C6E6EC-9CFE-47CA-8969-FD355628A120Q33328135-363EFE5E-E5BD-4166-8FED-4DF5E99FD23AQ33338978-5ED96043-2BF0-4043-95BF-11E2E38B15D6
P2860
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@ast
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@en
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@nl
type
label
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@ast
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@en
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@nl
prefLabel
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@ast
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@en
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@nl
P2093
P50
P356
P1476
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
@en
P2093
Barbara L Weber
Ellen Matloff
Henry T Lynch
Judy E Garber
Laura Van't Veer
Mary B Daly
Prevention and Observation of Surgical End Points Study Group
Timothy R Rebbeck
P304
P356
10.1056/NEJMOA012158
P407
P577
2002-05-20T00:00:00Z